Folgen
Fernando Vieira
Fernando Vieira
CEO and Chief Scientific Officer, ALS Therapy Development Institute
Bestätigte E-Mail-Adresse bei als.net
Titel
Zitiert von
Zitiert von
Jahr
Design, power, and interpretation of studies in the standard murine model of ALS
S Scott, JE Kranz, J Cole, JM Lincecum, K Thompson, N Kelly, A Bostrom, ...
Amyotrophic Lateral Sclerosis 9 (1), 4-15, 2008
5512008
Guidelines for preclinical animal research in ALS/MND: A consensus meeting
AC Ludolph, C Bendotti, E Blaugrund, A Chio, L Greensmith, JP Loeffler, ...
Amyotrophic Lateral Sclerosis 11 (1-2), 38-45, 2010
3302010
From transcriptome analysis to therapeutic anti-CD40L treatment in the SOD1 model of amyotrophic lateral sclerosis
JM Lincecum, FG Vieira, MZ Wang, K Thompson, GS De Zutter, J Kidd, ...
Nature genetics 42 (5), 392-399, 2010
1302010
Personalizing ASR for dysarthric and accented speech with limited data
J Shor, D Emanuel, O Lang, O Tuval, M Brenner, J Cattiau, F Vieira, ...
arXiv preprint arXiv:1907.13511, 2019
1072019
C57BL/6J congenic Prp-TDP43A315T mice develop progressive neurodegeneration in the myenteric plexus of the colon without exhibiting key features of ALS
T Hatzipetros, LP Bogdanik, VR Tassinari, JD Kidd, AJ Moreno, C Davis, ...
Brain research 1584, 59-72, 2014
1072014
A quick phenotypic neurological scoring system for evaluating disease progression in the SOD1-G93A mouse model of ALS
T Hatzipetros, JD Kidd, AJ Moreno, K Thompson, A Gill, FG Vieira
JoVE (Journal of Visualized Experiments), e53257, 2015
1002015
No benefit from chronic lithium dosing in a sibling-matched, gender balanced, investigator-blinded trial using a standard mouse model of familial ALS
A Gill, J Kidd, F Vieira, K Thompson, S Perrin
PLoS One 4 (8), e6489, 2009
1002009
Degeneration of proprioceptive sensory nerve endings in mice harboring amyotrophic lateral sclerosis–causing mutations
SK Vaughan, Z Kemp, T Hatzipetros, F Vieira, G Valdez
Journal of Comparative Neurology 523 (17), 2477-2494, 2015
852015
Guanabenz treatment accelerates disease in a mutant SOD1 mouse model of ALS
FG Vieira, Q Ping, AJ Moreno, JD Kidd, K Thompson, B Jiang, ...
PloS one 10 (8), e0135570, 2015
792015
SOD1-positive aggregate accumulation in the CNS predicts slower disease progression and increased longevity in a mutant SOD1 mouse model of ALS
C Gill, JP Phelan, T Hatzipetros, JD Kidd, VR Tassinari, B Levine, ...
Scientific reports 9 (1), 6724, 2019
742019
A human-derived antibody targets misfolded SOD1 and ameliorates motor symptoms in mouse models of amyotrophic lateral sclerosis
M Maier, T Welt, F Wirth, F Montrasio, D Preisig, J McAfoose, FG Vieira, ...
Science translational medicine 10 (470), eaah3924, 2018
732018
Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability
JD Berry, S Paganoni, N Atassi, EA Macklin, N Goyal, M Rivner, ...
Muscle & nerve 56 (6), 1077-1084, 2017
472017
Proteomic analysis reveals differentially regulated protein acetylation in human amyotrophic lateral sclerosis spinal cord
D Liu, C Liu, J Li, K Azadzoi, Y Yang, Z Fei, K Dou, NW Kowall, HP Choi, ...
PLoS One 8 (12), e80779, 2013
412013
CuATSM efficacy is independently replicated in a SOD1 mouse model of ALS while unmetallated ATSM therapy fails to reveal benefits
FG Vieira, T Hatzipetros, K Thompson, AJ Moreno, JD Kidd, VR Tassinari, ...
IBRO reports 2, 47-53, 2017
342017
The ALS-inducing factors, TDP43A315T and SOD1G93A, directly affect and sensitize sensory neurons to stress
SK Vaughan, NM Sutherland, S Zhang, T Hatzipetros, F Vieira, G Valdez
Scientific Reports 8 (1), 16582, 2018
252018
Dexpramipexole is ineffective in two models of ALS related neurodegeneration
FG Vieira, E LaDow, A Moreno, JD Kidd, B Levine, K Thompson, A Gill, ...
PLoS One 9 (12), e91608, 2014
252014
A machine-learning based objective measure for ALS disease severity
FG Vieira, S Venugopalan, AS Premasiri, M McNally, A Jansen, ...
NPJ digital medicine 5 (1), 45, 2022
182022
Method for the treatment of neurodegenerative diseases
S Perrin, JM Lincecum, A Gill, F Vieira
US Patent 8,435,514, 2013
152013
Type I PRMT inhibition protects against C9ORF72 arginine-rich dipeptide repeat toxicity
AS Premasiri, AL Gill, FG Vieira
Frontiers in Pharmacology 11, 569661, 2020
122020
Primary neurons and differentiated NSC-34 cells are more susceptible to arginine-rich ALS dipeptide repeat protein-associated toxicity than non-differentiated NSC-34 and CHO cells
AL Gill, MZ Wang, B Levine, A Premasiri, FG Vieira
International Journal of Molecular Sciences 20 (24), 6238, 2019
112019
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20